NICE recommended tucatinib in combination with trastuzumab and capecitabine as an option for treating HER2+ locally advanced breast cancer (LABC) or MBC in adults after two or more prior anti-HER2 therapies in April 2022 [12]. Here, ERBB2 is linked to breast carcinoma.